Nalls Sherbakoff Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

Nalls Sherbakoff Group’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$463	Hold	11	–	–	﹤0.01%	360
2026 Q1	$291	Hold	11	–	–	﹤0.01%	399
2025 Q4	$319	Hold	11	–	–	﹤0.01%	430
2025 Q3	$305	Hold	11	–	–	﹤0.01%	417
2025 Q2	$268	Sell	11 -12	-52%	-$263	﹤0.01%	418
2025 Q1	$477	Buy	+23	New	+$578	﹤0.01%	418
2023 Q4	$755	Hold	23	–	–	﹤0.01%	404
2023 Q3	$641	Hold	23	–	–	﹤0.01%	421
2023 Q2	$728	Hold	23	–	–	﹤0.01%	436
2023 Q1	$660	Buy	+23	New	+$713	﹤0.01%	469

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Nalls Sherbakoff Group's ARKG Position: Q2 2026 in Review

Nalls Sherbakoff Group held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 11 shares worth $463. The position accounts for ﹤0.01% of the portfolio, ranked #360.

Nalls Sherbakoff Group first reported a position in ARKG in Q1 2023 and has held it in 10 quarters since. The position peaked at $755 in Q4 2023. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Nalls Sherbakoff Group held 11 shares of ARK Genomic Revolution ETF worth $463 as of Q2 2026.
Nalls Sherbakoff Group left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q2 2026, its #360 holding.
Nalls Sherbakoff Group first reported a position in ARK Genomic Revolution ETF in Q1 2023 and has held it in 10 quarters since.
Nalls Sherbakoff Group's ARK Genomic Revolution ETF position peaked at $755 in Q4 2023.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Nalls Sherbakoff Group's 13F filing for Q2 2026, filed 17 Aug 2026.